Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Adma Biologics Inc shares valued at $158,069 were sold by Guiheen Lawrence P. on May 21 ’25. At $20.32 per share, Guiheen Lawrence P. sold 7,779 shares. The insider’s holdings dropped to 114,830 shares worth approximately $2.27 million following the completion of this transaction.
Also, Guiheen Lawrence P. sold 1,221 shares, netting a total of over 24,567 in proceeds. Following the sale of shares at $20.12 each, the insider now holds 114,830 shares.
Before that, Guiheen Lawrence P. had added 9,000 shares to its account. In a trade valued at $183,960, the Director bought Adma Biologics Inc shares for $20.44 each.
Analysts at Mizuho started covering the stock with ‘”a Buy”‘ outlook in a report released in mid October. As of November 11, 2021, Raymond James has increased its “an Outperform” rating to a “Strong buy” for ADMA. Earlier on November 09, 2021, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for ADMA stock.
Analyzing ADMA Stock Performance
During the last five days, there has been a drop of approximately -1.74%. Over the course of the year, Adma Biologics Inc shares have jumped approximately 15.28%. Shares of the company reached a 52-week high of $25.67 on 04/28/25 and a 52-week low of $13.50 on 03/04/25.
Support And Resistance Levels for Adma Biologics Inc (ADMA)
According to the 24-hour chart, there is a support level at 19.40, which, if violated, would cause prices to drop to 19.03. In the upper region, resistance lies at 20.14. The next price resistance is at 20.51. RSI (Relative Strength Index) is 44.54 on the 14-day chart, showing neutral technical sentiment.
